We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$405M
Cap. Flow
% of AUM
-13.51%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
104
New
28
Increased
19
Reduced
31
Closed
14
Top Buys
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
GENB
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| 1 | Healthcare | 87.27% |
| 2 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
1
Caris Life Sciences
CAI
$4.94B
| $143M | 4.78% |
8,009,447
+193,305
| +2% | +$4.23M |
|
2
Neurocrine Biosciences
NBIX
$17.3B
| $85.9M | 2.87% |
652,121
-99,413
| -13% | -$13.2M |
|
3
Glaukos
GKOS
$9.21B
| $82.2M | 2.74% |
763,505
-158,474
| -17% | -$17.8M |
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $78.9M | 2.63% |
1,986,768
-201,552
| -9% | -$5.16M |
|
5
Xenon Pharmaceuticals
XENE
$6.55B
| $77.8M | 2.6% |
1,338,452
-486,624
| -27% | -$22.4M |
|
6
Dianthus Therapeutics
DNTH
$5.46B
| $75.5M | 2.52% |
899,364
-374,571
| -29% | -$21.7M |
|
|
7
Edgewise Therapeutics
EWTX
$4.39B
| $73.9M | 2.47% |
2,347,583
-2,863,248
| -55% | -$82.6M |
|
|
8
iRhythm Holdings
IRTC
$3.72B
| $72M | 2.4% |
610,192
+392,847
| +181% | +$56.7M |
|
9
Nuvalent
NUVL
$9.81B
| $71.8M | 2.39% |
700,429
-120,977
| -15% | -$12.3M |
|
10
Kodiak Sciences
KOD
$2.65B
| $69.3M | 2.31% |
1,818,665
-254,123
| -12% | -$6.57M |
|
|
11
CG Oncology
CGON
$6.44B
| $66.7M | 2.22% |
984,783
-885,788
| -47% | -$50.2M |
|
|
12
argenx
ARGX
$54B
| $62M | 2.07% |
84,939
+53,932
| +174% | +$42.2M |
|
|
HNGE
13
Hinge Health
HNGE
$6.64B
| $56.1M | 1.87% |
1,455,123
+150,500
| +12% | +$6.25M |
|
14
Acadia Pharmaceuticals
ACAD
$4.44B
| $55M | 1.84% |
2,471,199
+439,178
| +22% | +$10.5M |
|
|
15
Monte Rosa Therapeutics
GLUE
$1.98B
| $52.7M | 1.76% |
3,206,574
+2,258,258
| +238% | +$43.2M |
|
16
Krystal Biotech
KRYS
$10.3B
| $47.1M | 1.57% |
182,425
-19,676
| -10% | -$5.24M |
|
17
Spyre Therapeutics
SYRE
$8.86B
| $47.1M | 1.57% |
932,823
-701,792
| -43% | -$26.5M |
|
|
18
Guardant Health
GH
$21.6B
| $46.2M | 1.54% |
+499,712
| New | +$50.2M |
|
19
Thermo Fisher Scientific
TMO
$199B
| $45.7M | 1.52% |
92,915
+12,190
| +15% | +$6.62M |
|
|
GENB
20
Generate Biomedicines
GENB
$1.8B
| $44.9M | 1.5% |
+3,592,999
| New | +$43.9M |
|
|
MBX
21
MBX Biosciences
MBX
$2.89B
| $44.6M | 1.49% |
1,492,467
+473,867
| +47% | +$16.1M |
|
22
BrightSpring Health Services
BTSG
$13.4B
| $43.3M | 1.44% |
1,016,562
-179,224
| -15% | -$7.22M |
|
23
Celldex Therapeutics
CLDX
$3.01B
| $43M | 1.43% |
1,356,082
-502,027
| -27% | -$13.7M |
|
24
NeoGenomics
NEO
$1.89B
| $41.7M | 1.39% |
5,617,402
+984,601
| +21% | +$10.4M |
|
25
Apogee Therapeutics
APGE
$10.2B
| $40.3M | 1.34% |
478,667
-96,400
| -17% | -$7M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM